<p>Seres Therapeutics, Inc.（纳斯达克代码：MCRB - 获取免费报告）内部人士 Matthew Henn 于 11 月 15 日星期六出售了 1,257 股 Seres Therapeutics 股票。该股票的平均售价为 17.30 美元，总交易额为 21,746.10 美元。交易完成后，该内部人士直接持有 7,527 股公司股票，价值 130,217.10 美元。此次交易使其持股减少了 14.31%。该出售在向证券交易委员会的备案中披露，相关信息可通过此链接访问。</p>
<p>获取 <strong>Seres Therapeutics</strong> 的提醒：</p>
<h2>Seres Therapeutics 价格表现</h2>
<p>在周二的午盘交易中，纳斯达克 MCRB 的股票上涨了 3.07 美元，达到了 24.71 美元。该公司的 890,977 股股票成交量相比其平均成交量 121,438 股有所增加。Seres Therapeutics, Inc.的 1 年最低价为 6.53 美元，1 年最高价为 25.85 美元。该公司的 50 日移动平均价为 17.74 美元，200 日移动平均价为 13.97 美元。公司的市值为 2.2355 亿美元，市盈率为-5.48，贝塔值为 0.19。</p>
<h2>分析师设定新目标价</h2>
<p>MCRB 近期成为多份研究报告的主题。Weiss Ratings 在周一的报告中重申了对 Seres Therapeutics 股票的 “卖出（d）” 评级。Canaccord Genuity Group 在 9 月 24 日的研究报告中将 Seres Therapeutics 的目标价从 14.00 美元上调至 22.00 美元，并给予该股票 “买入” 评级。一位投资分析师对该股票给予了买入评级，一位给予了持有评级，另外两位则对该公司给予了卖出评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “减持”，平均目标价为 14.33 美元。</p>
<p><strong>查看我们对 Seres Therapeutics 的最新分析</strong></p>
<h2>对 Seres Therapeutics 的对冲基金看法</h2>
<p>对冲基金近期买入和卖出了该公司的股票。高盛集团在第一季度将其在 Seres Therapeutics 的持股增加了 40.9%。高盛集团目前持有 74,629 股生物技术公司的股票，价值 52,000 美元，此前在上个季度购买了 21,679 股。景顺投资公司在第一季度将其在 Seres Therapeutics 的股份增加了 193.2%。景顺投资公司目前持有 136,572 股生物技术公司的股票，价值 96,000 美元，此前在该期间购买了 89,995 股。美国银行在第三季度将其在 Seres Therapeutics 的持股增加了 2,772.6%。美国银行目前持有 5,343 股生物技术公司的股票，价值 103,000 美元，此前在上个季度购买了 5,157 股。XTX Topco Ltd 在第二季度购买了 Seres Therapeutics 的新股份，价值约 249,000 美元。最后，Schonfeld Strategic Advisors LLC 在第三季度购买了 Seres Therapeutics 的新股份，价值约 557,000 美元。机构投资者持有该公司 59.34% 的股票。</p>
<h2>关于 Seres Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Seres Therapeutics, Inc.是一家微生物组治疗公司，开发微生物组治疗以调节结肠微生物组。它开发了一类新型生物药物，旨在通过调节微生物组来恢复健康，修复受损微生物组的功能，使其恢复到非疾病状态。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票而非 Seres Therapeutics</li>
<li>医疗保健股票解析：为什么你可能想要投资</li>
<li>感恩节餐桌上有什么？每道菜的股票推荐</li>
<li>成长股：它们是什么，示例及如何投资</li>
<li>为什么家得宝的痛苦可能是长期投资者的收益</li>
<li>内部购买解析：投资者需要知道什么</li>
<li>高通的多头们正在失去犯错的空间</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUNSQg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUNSQg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Seres Therapeutics 吗？</h2>
<p>在你考虑 Seres Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Seres Therapeutics 并不在名单上。</p>
<p>虽然 Seres Therapeutics 目前在分析师中获得了减持评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

Seres治疗

<p>Matthew Henn，Seres Therapeutics 的内部人士，以每股 17.30 美元的价格出售了 1,257 股，总计 21,746.10 美元。此次出售使他的持股减少了 14.31%，剩余 7,527 股，价值 130,217.10 美元。该交易已在美国证券交易委员会（SEC）备案。Seres Therapeutics 的股价上涨至 24.71 美元，市值为 2.2355 亿美元。分析师对该股票的评级不一，Canaccord Genuity Group 最近将其目标价上调至 22.00 美元。机构投资者持有该公司 59.34% 的股份</p>

<p>Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) insider Matthew Henn sold 1,257 shares of Seres Therapeutics stock in a transaction on Saturday, November 15th. The stock was sold at an average price of $17.30, for a total transaction of $21,746.10. Following the completion of the transaction, the insider directly owned 7,527 shares of the company's stock, valued at $130,217.10. The trade was a 14.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink.</p>
<div class="lb-trans"><p>Seres Therapeutics, Inc.（纳斯达克代码：MCRB - 获取免费报告）内部人士 Matthew Henn 于 11 月 15 日星期六出售了 1,257 股 Seres Therapeutics 股票。该股票的平均售价为 17.30 美元，总交易额为 21,746.10 美元。交易完成后，该内部人士直接持有 7,527 股公司股票，价值 130,217.10 美元。此次交易使其持股减少了 14.31%。该出售在向证券交易委员会的备案中披露，相关信息可通过此链接访问。</p>
</div><p>Get <strong>Seres Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Seres Therapeutics</strong> 的提醒：</p>
</div><h2>Seres Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Seres Therapeutics 价格表现</h2>
</div><p>Shares of NASDAQ MCRB traded up $3.07 during mid-day trading on Tuesday, hitting $24.71. 890,977 shares of the company's stock traded hands, compared to its average volume of 121,438. Seres Therapeutics, Inc. has a 1 year low of $6.53 and a 1 year high of $25.85. The company's 50-day moving average is $17.74 and its two-hundred day moving average is $13.97. The company has a market capitalization of $223.55 million, a P/E ratio of -5.48 and a beta of 0.19.</p>
<div class="lb-trans"><p>在周二的午盘交易中，纳斯达克 MCRB 的股票上涨了 3.07 美元，达到了 24.71 美元。该公司的 890,977 股股票成交量相比其平均成交量 121,438 股有所增加。Seres Therapeutics, Inc.的 1 年最低价为 6.53 美元，1 年最高价为 25.85 美元。该公司的 50 日移动平均价为 17.74 美元，200 日移动平均价为 13.97 美元。公司的市值为 2.2355 亿美元，市盈率为-5.48，贝塔值为 0.19。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>MCRB has been the subject of a number of recent research reports. Weiss Ratings reiterated a &#34;sell (d)&#34; rating on shares of Seres Therapeutics in a report on Monday. Canaccord Genuity Group raised their price target on Seres Therapeutics from $14.00 to $22.00 and gave the stock a &#34;buy&#34; rating in a research report on Wednesday, September 24th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of &#34;Reduce&#34; and an average target price of $14.33.</p>
<div class="lb-trans"><p>MCRB 近期成为多份研究报告的主题。Weiss Ratings 在周一的报告中重申了对 Seres Therapeutics 股票的 “卖出（d）” 评级。Canaccord Genuity Group 在 9 月 24 日的研究报告中将 Seres Therapeutics 的目标价从 14.00 美元上调至 22.00 美元，并给予该股票 “买入” 评级。一位投资分析师对该股票给予了买入评级，一位给予了持有评级，另外两位则对该公司给予了卖出评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “减持”，平均目标价为 14.33 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on Seres Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Seres Therapeutics 的最新分析</strong></p>
</div><h2>Hedge Funds Weigh In On Seres Therapeutics</h2>
<div class="lb-trans"><h2>对 Seres Therapeutics 的对冲基金看法</h2>
</div><p>Hedge funds have recently bought and sold shares of the business. Goldman Sachs Group Inc. lifted its position in shares of Seres Therapeutics by 40.9% during the first quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company's stock worth $52,000 after purchasing an additional 21,679 shares during the last quarter. Invesco Ltd. increased its stake in Seres Therapeutics by 193.2% in the 1st quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company's stock worth $96,000 after buying an additional 89,995 shares during the period. Bank of America Corp DE lifted its holdings in Seres Therapeutics by 2,772.6% during the 3rd quarter. Bank of America Corp DE now owns 5,343 shares of the biotechnology company's stock valued at $103,000 after buying an additional 5,157 shares in the last quarter. XTX Topco Ltd bought a new stake in Seres Therapeutics during the 2nd quarter valued at about $249,000. Finally, Schonfeld Strategic Advisors LLC purchased a new stake in Seres Therapeutics in the 3rd quarter valued at about $557,000. Institutional investors own 59.34% of the company's stock.</p>
<div class="lb-trans"><p>对冲基金近期买入和卖出了该公司的股票。高盛集团在第一季度将其在 Seres Therapeutics 的持股增加了 40.9%。高盛集团目前持有 74,629 股生物技术公司的股票，价值 52,000 美元，此前在上个季度购买了 21,679 股。景顺投资公司在第一季度将其在 Seres Therapeutics 的股份增加了 193.2%。景顺投资公司目前持有 136,572 股生物技术公司的股票，价值 96,000 美元，此前在该期间购买了 89,995 股。美国银行在第三季度将其在 Seres Therapeutics 的持股增加了 2,772.6%。美国银行目前持有 5,343 股生物技术公司的股票，价值 103,000 美元，此前在上个季度购买了 5,157 股。XTX Topco Ltd 在第二季度购买了 Seres Therapeutics 的新股份，价值约 249,000 美元。最后，Schonfeld Strategic Advisors LLC 在第三季度购买了 Seres Therapeutics 的新股份，价值约 557,000 美元。机构投资者持有该公司 59.34% 的股票。</p>
</div><h2>About Seres Therapeutics</h2>
<div class="lb-trans"><h2>关于 Seres Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.</p>
<div class="lb-trans"><p>Seres Therapeutics, Inc.是一家微生物组治疗公司，开发微生物组治疗以调节结肠微生物组。它开发了一类新型生物药物，旨在通过调节微生物组来恢复健康，修复受损微生物组的功能，使其恢复到非疾病状态。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Seres Therapeutics</li>
<li>Health Care Stocks Explained: Why You Might Want to Invest</li>
<li>What’s on the Thanksgiving Table? A Stock Pick for Every Course</li>
<li>Growth Stocks: What They Are, Examples and How to Invest</li>
<li>Why Home Depot’s Pain Could Be a Long-Term Investor’s Gain</li>
<li>Insider Buying Explained: What Investors Need to Know</li>
<li>Qualcomm’s Bulls Are Running Out of Room to Be Wrong</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票而非 Seres Therapeutics</li>
<li>医疗保健股票解析：为什么你可能想要投资</li>
<li>感恩节餐桌上有什么？每道菜的股票推荐</li>
<li>成长股：它们是什么，示例及如何投资</li>
<li>为什么家得宝的痛苦可能是长期投资者的收益</li>
<li>内部购买解析：投资者需要知道什么</li>
<li>高通的多头们正在失去犯错的空间</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUNSQg" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=MCRB"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Seres Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Seres Therapeutics 吗？</h2>
</div><p>Before you consider Seres Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Seres Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Seres Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Seres Therapeutics 并不在名单上。</p>
</div><p>While Seres Therapeutics currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Seres Therapeutics 目前在分析师中获得了减持评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

内部人士出售：Seres 治疗（纳斯达克代码：MCRB）的一位内部人士出售了 1,257 股股票